KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Assets: 2018-2025

Historic Assets for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $562.8 million.

  • Castle Biosciences' Assets rose 9.37% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.8 million, marking a year-over-year increase of 9.37%. This contributed to the annual value of $531.2 million for FY2024, which is 17.18% up from last year.
  • As of Q3 2025, Castle Biosciences' Assets stood at $562.8 million, which was up 3.31% from $544.7 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Assets high stood at $562.8 million for Q3 2025, and its period low was $425.4 million during Q2 2023.
  • In the last 3 years, Castle Biosciences' Assets had a median value of $487.3 million in 2024 and averaged $485.7 million.
  • In the last 5 years, Castle Biosciences' Assets skyrocketed by 263.66% in 2021 and then decreased by 7.19% in 2023.
  • Over the past 5 years, Castle Biosciences' Assets (Quarterly) stood at $462.6 million in 2021, then decreased by 3.30% to $447.3 million in 2022, then rose by 1.34% to $453.3 million in 2023, then increased by 17.18% to $531.2 million in 2024, then rose by 9.37% to $562.8 million in 2025.
  • Its Assets stands at $562.8 million for Q3 2025, versus $544.7 million for Q2 2025 and $501.7 million for Q1 2025.